Pim G N J Mutsaers Selected Research

COVID-19

7/2023	Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
10/2022	Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
1/2022	Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients.
1/2022	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.
1/2022	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pim G N J Mutsaers Research Topics

Disease

7	Neoplasms (Cancer) 07/2023 - 07/2004
5	COVID-19 07/2023 - 01/2022
2	B-Cell Lymphoma (Lymphoma, B Cell) 08/2023 - 10/2022
2	T-Cell Lymphoma (Lymphoma, T Cell) 11/2022 - 01/2022
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2022 - 01/2022
2	Multiple Myeloma 10/2022 - 01/2022
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2023
1	Bronchiolitis Obliterans Syndrome 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2022
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2022
1	Respiratory Insufficiency (Respiratory Failure) 12/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2021

Drug/Important Bio-Agent (IBA)

3	Chimeric Antigen ReceptorsIBA 08/2023 - 01/2022
2	AntibodiesIBA 07/2023 - 10/2022
2	Immunoglobulin G (IgG)IBA 07/2023 - 01/2022
2	Etoposide (VP 16)FDA LinkGeneric 11/2022 - 01/2022
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2022 - 01/2022
2	Vincristine (Oncovin)FDA LinkGeneric 11/2022 - 01/2022
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2022 - 01/2022
2	Prednisone (Sone)FDA LinkGeneric 11/2022 - 01/2022
2	ibrutinibIBA 10/2022 - 01/2022
2	2019-nCoV Vaccine mRNA-1273IBA 10/2022 - 01/2022
1	Proteins (Proteins, Gene)FDA Link 07/2023
1	N-(2-cyanoethylene)urea (BA 1)IBA 07/2023
1	Messenger RNA (mRNA)IBA 07/2023
1	Cell-Free Nucleic AcidsIBA 01/2023
1	Rituximab (Mabthera)FDA Link 11/2022
1	Neutralizing AntibodiesIBA 10/2022
1	AnthracyclinesIBA 01/2022
1	Oxygen (Dioxygen)IBA 01/2022
1	ruxolitinibIBA 01/2022
1	tocilizumab (atlizumab)FDA Link 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 12/2021

Therapy/Procedure

4	Therapeutics 08/2023 - 01/2022
3	Drug Therapy (Chemotherapy) 01/2022 - 07/2004
2	Cell Transplantation 10/2022 - 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2022
1	Aftercare (After-Treatment) 10/2022
1	Transplantation 10/2022